Abstract
761P Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have